PATENT CLAIM ANALYSIS

Application Number: 16233890
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "100000"]

Abstract:
The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.

Claim (Index 87):
The method of  claim 85 , wherein the insulinotropic peptide is selected from the group consisting of a native exendin-4; an exendin-4 derivative in which the N-terminal amine group of exendin-4 is deleted; an exendin-4 derivative in which the N-terminal amine group of exendin-4 is substituted with a hydroxyl group; an exendin-4 derivative in which the N-terminal amine group of exendin-4 is modified with a dimethyl group; an exendin-4 derivative in which the \u03b1-carbon of the 1 st  amino acid of exendin-4, histidine, is deleted; an exendin-4 derivative in which the 12 th  amino acid of exendin-4, lysine, is substituted with serine, and an exendin-4 derivative in which the 12 th  amino acid of exendin-4, lysine, is substituted with arginine.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.48148
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15740668', '13810999', '16024014', '15313501', '15086499']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8302185499356054
- 35 USC 102 Novelty (BERT): 0.6765563555050652
- Combined Prediction Score: 0.8148523304925515
- Mean Citation Score: 452.842674
- Max Citation Score: 747.8688
- Similarity Product: 652.9838945869445

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test